| NCT ID | NCT05634681 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | Cervix Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 190 participants |
| Start Date | 2022-11-13 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 190 participants in total. It began in 2022-11-13 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study objectives are to improve the treatment of LACC patients and to increase knowledge of the potential benefit of the plan-of-the-day concept on side effects during and after radiotherapy.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed cervical cancer eligible for definitve radiochemotherapy * FIGO stage IB1-IVa * Over 18 years * Speaks and understands Norwegian or English. * ECOG 0-2 * Histology: Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma * Ability to understand and fill in patient questionnaires, and willing to sign a written informed consent * Large movers (LM), fundus movement ≥2,5 cm. Exclusion Criteria: * Evidence of distant metastasis. Suspicious paraaortic lymphnodes below the renal vessels is allowed if they are covered by the radiation field * Patients with previous surgery for their cervical cancer * Uncontrolled intercurrent somatic illness. * Psychiatric illness /social situations limiting study compliance * Prior radiotherapy to the pelvis * Patients who are pregnant or breastfeeding is excluded due to risk of teratogenic and abortifacient effects of radiotherapy and cisplatin, and the potential risk of adverse effect of nursing infants * Patients under current treatment for other invasive s except non-melanoma skin cancers * Nephrostomy * Patients with inflammatory bowel disease
Contact & Investigator
Kjersti Bruheim, MD PhD
PRINCIPAL INVESTIGATOR
Oslo University Hospital
Frequently Asked Questions
Who can join the NCT05634681 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Cervix Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05634681 currently recruiting?
Yes, NCT05634681 is actively recruiting participants. Contact the research team at uxkjuh@ous-hf.no for enrollment information.
Where is the NCT05634681 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT05634681 clinical trial?
NCT05634681 is sponsored by Oslo University Hospital. The principal investigator is Kjersti Bruheim, MD PhD at Oslo University Hospital. The trial plans to enroll 190 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.